高级检索
    李京, 李莎燕, 程亮, 戴琰琨, 丁明胜, 王小清, 郝海荣, 俞伟男, 胡文. 2型糖尿病患者血红蛋白与糖尿病足风险的相关性研究[J]. 徐州医科大学学报, 2022, 42(1): 30-35. DOI: 10.3969/j.issn.2096-3882.2022.01.006
    引用本文: 李京, 李莎燕, 程亮, 戴琰琨, 丁明胜, 王小清, 郝海荣, 俞伟男, 胡文. 2型糖尿病患者血红蛋白与糖尿病足风险的相关性研究[J]. 徐州医科大学学报, 2022, 42(1): 30-35. DOI: 10.3969/j.issn.2096-3882.2022.01.006
    A study on the correlation between the level of hemoglobin and the risk of diabetic foot in patients with type 2 diabetes[J]. Journal of Xuzhou Medical University, 2022, 42(1): 30-35. DOI: 10.3969/j.issn.2096-3882.2022.01.006
    Citation: A study on the correlation between the level of hemoglobin and the risk of diabetic foot in patients with type 2 diabetes[J]. Journal of Xuzhou Medical University, 2022, 42(1): 30-35. DOI: 10.3969/j.issn.2096-3882.2022.01.006

    2型糖尿病患者血红蛋白与糖尿病足风险的相关性研究

    A study on the correlation between the level of hemoglobin and the risk of diabetic foot in patients with type 2 diabetes

    • 摘要: 目的 探讨2型糖尿病(Type 2 diabetes mellitus, T2DM)患者血红蛋白(Hemoglobin, Hb)水平与糖尿病足风险的相关性。方法 选取2018年6月1日至2020年3月30日徐州医科大学附属淮安医院内分泌科T2DM住院患者145人为研究对象,根据有无并发糖尿病足(diabetic foot, DF)将其分为DF组和non-DF组。收集患者基本资料,采取血样本送本院生化中心检测生化、血常规相关指标。采用独立样本t检验、卡方检验比较两组差异;单因素二元logistic回归分析评估各项临床指标与DF风险的相关性;多因素二元logistic回归分析Hb与DF风险的相关性。结果 DF组患者糖尿病(diabetes mellitus, DM)病程、血肌酐(Scr)、C反应蛋白(CRP)明显高于non-DF组(P<0.05),而预估肾小球滤过率(eGFR)、Hb、白蛋白(Alb)、总胆固醇(TC)则相反,明显低于non-DF组(P<0.05)。两组患者年龄、性别、体质指数(BMI)、收缩压(SBP)、舒张压(DBP)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)比较,差异无统计学意义(P > 0.05)。根据eGFR水平分为eGFR ≥ 90 mL/(min*1.73m2)和eGFR < 90 mL/(min*1.73m2)两层,eGFR ≥ 90 mL/(min*1.73m2)中,Hb、Alb是DF的保护因素,Hb、Alb越低,发病率越高(P<0.05)。而在eGFR < 90 mL/(min*1.73m2)中却无明显统计学意义(P < 0.05)。结论 T2DM患者的Hb水平是DF的保护因素,低Hb是DF患病的独立危险因素,为DF的防治提供临床理论依据。(临床实验注册机构:淮安市第二人民医院伦理委员会 临床试验号:HEYLL201924)。

       

      Abstract: ob<x>jective To explore the correlation between Hb level and risk of DF in patients with Type 2 diabetes mellitus (T2DM). Methods A total of 145 inpatients with T2DM were recruited from Endocrinology Department, the Affiliated Huaian Hospital of Xuzhou Medical University from June 1, 2018 to March 30, 2020. They were divided into DF group and non-DF group according to the presence or absence of DF. The basic data of patients were obtained and their blood sample was collected to the biochemical center of our hospital to detect biochemical and blood routine related indicators. Independent sample t test and Chi-square test were used to compare the differences between the two groups. The correlation of various clinical indicators with DF risk were evaluated by single-factor binary logistic regression analysis. And multi-factor binary logistic regression analysis was used to analyze the correlation between Hb level and DF risk. Results The duration of diabetes, serum creatinine(Scr), and C-reactive protein(CRP)in the DF group were significantly higher than those in the non-DF group(P<0.05). On the contrary, the estimated glomerular filtration rate(eGFR),hemoglobin (Hb), albumin(Alb), and total cholesterol (TC)were inversely lower than those in the non-DF group(P<0.05). There were no significant differences in age, gender, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, fasting blood glucose (FPG), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high Comparison of density lipoprotein cholesterol (HDL-C) between the two groups (P>0.05). According to eGFR level, All subjects were divided into two groups: eGFR≥90mL/(min*1.73m2) and eGFR<90mL/(min*1.73m2). Hb and Alb, two protective factors, had a positive impact on the occurrence and development of DF, especially in people that their eGFR was greater than or equal to 90mL/(min*1.73m2)(P<0.05). As the lower the Hb and Alb were, the higher the incidence of the DF was. However, no significance was found between these indicators and DF in the group that eGFR less than 90mL/(min*1.73m2) (P>0.05). Conclusion The Hb level of T2DM patients is a protective factor of DF and low Hb is an independent risk factor of DF. The study may provide clinical theoretical basis for the prevention and treatment of DF.(Clinical trial registration agency:Ethics Committee of Huai’an Second People’s Hospital Clinical trial number: HEYLL201924)

       

    /

    返回文章
    返回